Cognito's $105 million Series C will advance their pivotal FDA study, expand clinical neurology partnerships, and expand work past Alzheimer's into Parkinsons and beyond.

The Massachusetts-based company will use the funds to advance its Spectris neurotechnology platform that uses visual and auditory stimulation to treat Alzheimer’s disease.

Cognito Therapeutics, which is in late-stage development of its device to treat neurodegenerative diseases like Alzheimer’s, hauled in ...

Series C proceeds position Spectris for pivotal top-line data, regulatory submission, and launch planning ahead of a targeted ...

Cognito Therapeutics Announces Oversubscribed $105 Million Series C Financing to Advance Spectris™ in Alzheimer’s Disease ...

In 2026, the digital wellness landscape transitioned from a collection of lifestyle novelties into a vital, data-driven ...

Cognito Therapeutics today announced that it completed the final close of its oversubscribed Series C financing round.

Cognito Therapeutics, a late clinical-stage neurotechnology company pioneering non-invasive neuroprotective therapies in neurodegenerative diseases, today announced the final close of its ...

Louisiana used it as an opportunity to promote the City of Rayne as the Frog Capital of the World. See how the frogs helped ...

The Cosmic Shambles Forest will present an expanded experience at Latitude Festival 2026, featuring two stages, a Museum ...

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company developing therapeutics based on its ...

The Cosmic Shambles​ Forest is returning to Latitude this summer, with a string of science and culture events programmed by comedian Robin Ince and producer Trent Burton ...